CD274 and non-small cell lung carcinoma: The maximum 20 increase of NHB were seen in three indications: pembrolizumab as second line therapy for advanced urothelial carcinoma (KETNOTE-045 trial) [17, 18], pembrolizumab as first-line NSCLC with tumors express PD-L1 > 50% as determined by an FDA-approved test (KETNOTE-024 trial) [19, 20], and nivolumab as second line therapy of advanced nonsquamous NSCLC (CHECKMATE-057 trial) [21, 22].